Lipid particles and suspensions and uses thereof

• US 20060078618A1
• Filed: 12/11/2002
• Published: 04/13/2006
• Est. Priority Date: 12/11/2001
• Status: Abandoned Application

• Current Assignee: Likan Liang, Panayiotis P Constantinides, Reena T. Patil
• Original Assignee: Likan Liang, Panayiotis P Constantinides, Reena T. Patil
• Inventors: Liang, Likan, Constantinides, Panayiotis P, Patil, Reena T
• Application Number:
  US10/498,572
• Publication Number:
  US 20060078618A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

The present invention relates to formulations and methods for the mucosal and parenteral administration of lipid particles an suspensions. The formulations of this invention are stable lipid particles useful for oral delivery of water-insoluble therapeutic agents, vaccines and diagnostics. The compositions of this invention promote the mucosal absorption of biologically active molecules across mucosal epithelial barriers. Stabilization of lipid particles is achieved by coating the hydrophobic central core with a polymer shell. The polymer shell can include bioadhesive agents, ligands, and absorption promoting agents. This invention relates to oral drug delivery systems for hydrophobic drugs, and in particular is concerned with improving the bioavailability of hydrophobic drugs from such systems. Using this system, anticancer drugs such as taxanes are orally effective.

Claims

1. A particle composition that comprises

(a) a hydrophobic phase;

(b) a surfactant;

(c) a biologically active agent; and

(d) a polymeric stabilizer.

2. The particle composition of claim 1 wherein the hydrophobic phase comprises an oil or mixture of oils.

3. The particle composition of claim 2 wherein the oil is a triglyceride.

4. The particle composition of claim 1 wherein the hydrophobic phase comprises a triglyceride that is liquid between 10°

C. and 45°

C.

5. The particle composition of claim 1 wherein the hydrophobic phase comprises a triglyceride that is liquid between 10°

C. and 70°

C.

6. The particle composition of claim 1 wherein the surfactant is selected from the group consisting of an alkyl glycerolphosphoryl choline, a polyoxyethylene polymer, a block copolymer of polyoxyethylene and polyoxypropylene, and an ethoxylated glycerol ester.

7. The particle composition of claim 1, wherein the surfactant comprises one or more glycerol fatty acid esters or hydrophilic derivatives thereof.

8. The particle composition of claim 7, wherein the fatty acid esters have a length of about 6 to about 12 carbon atoms.

9. The particle composition of claim 1, wherein surfactant comprises a monoglyceride, diglyceride or mixture thereof.

10. The particle composition of claim 1, wherein the surfactant comprises a monoglyceride or a hydrophilic derivative or analog thereof.

11. The particle composition of claim 1, wherein the surfactant comprises a diglyceride or a hydrophilic derivative or analog thereof.

12. The particle composition of claim 1, wherein the surfactant comprises a monoglyceride or diglyceride mixture.

13. The particle composition of claim 6, wherein the surfactant further comprises a diglyceride or a hydrophilic derivative or analog thereof.

14. The particle composition of claim 1, wherein the particle suspension further comprises a solvent selected from the group consisting of water, glycerol, sorbitol, mannitol, propylene glycol, ethylene glycol, polyethylene glycol or mixtures thereof.

15. The particle composition of claim 1, wherein the particle suspension further comprises a solvent selected from the group consisting of a monoterpene or a derivative thereof.

16. The particle composition of claim 15, wherein the monoterpene is perillyl alcohol, perillic acid or d-limonene.

17. The particle composition of claim 10, wherein the monoglyceride is derivatized by a polyoxyethylene polymer.

18. The particle composition of claim 10, wherein the monoglyceride is derivatized by a polyoxyethylene polymer from about 200 to about 10,000 in molecular weight.

19. The particle composition of claim 10, wherein the monoglyceride is derivatized by a polyoxyethylene polymer from about 200 to about 4,000 in molecular weight.

20. The particle composition of claim 11, wherein the diglyceride is derivatized by a polyoxyethylene polymer.

21. The particle composition of claim 3, wherein at least one of the fatty acid esters of said triglyceride is derivatized with acetic acid, citric acid, lactic acid, succinic acid, tartaric acid or mixtures thereof.

22. The particle composition of claim 7, wherein at least one of the fatty acid esters is a caprylic acid or capric acid.

23. The particle composition of claim 1, wherein the polymeric stabilizer is a natural polymer, a synthetic polymer or a mixture thereof.

24. The particle composition of claims 1 or 23, wherein the polymeric stabilizer is a polymerizable fatty acid or phospholipid.

25. The particle composition of claim 24, wherein the polymeric stabilizer is ODP or OPS.

26. The particle composition of claim 24, wherein the polymer is formed from a polymerizable fatty acid monomer.

27. The particle composition of claim 1 wherein said composition is in the form of a polymer, said polymer formed by interfacial ionic polymerization with water or other initiators.

28. The particle composition of claim 23, wherein said composition is in the form of a polymer, said polymer formed by condensation of cyanoacrylates, including alkylcyanoacrylates.

29. The particle composition of claim 23, wherein the polymer is formed from condensation of ethyl 2-cyanoacrylate.

30. The particle composition of claim 23, wherein the synthetic polymer is selected from the group consisting of polylactide, polyglycolide, a mixture of polylactide and polyglycolide, a polycaprolactone,a polyortho esters, polysebacic acid, polyfumaric acid, polyamides, polycarbonates, polyalkylenes, polyacrylamides, poly(hydroxy acids), polyanhydrides, polyorth oesters, polyacrylate, polyvinyl alcohols, blends or copolymers thereof.

31. The particle composition of claim 1, wherein the particle is suspended in a aqueous phase comprising an additive selected from:

the group consisting of a suspending agent, buffering agent, a tonicity agent, an oxidizing agent, a reducing agent, an antimicrobial agent, a preservative, a stabilizing agent, or a mixture thereof.

32. The particle composition of claim 1, wherein the hydrophobic phase is present in an amount from about 0% to about 50% by weight of the particle composition.

33. The particle composition of claim 1, wherein the hydrophobic phase is present in an amount from about 0% to about 50% by weight of the particle composition.

34. The particle composition of claim 1, wherein.the hydrophilic phase is present in an amount from about 10% to 25% by weight of the particle composition.

35. The particle composition of claim 1, wherein the surfactant has an HLB value of about 1 to about 45.

36. The particle composition of claim 1, wherein the surfactant has an HLB of about 1 to about 20.

37. The particle composition of claim 1, wherein the biologically active molecule is a prophylactic or therapeutic agent.

38. The particle composition of claim 1, wherein the biologically active molecule is a diagnostic agent.

39. The particle composition of claim 37, wherein the therapeutic agent is a taxane or an analog thereof.

40. The particle composition of claim 1 or 37, wherein the therapeutic agent is paclitaxel.

41. The particle composition of claim 1, wherein the biologically active molecule is a topisomerase inhibitor.

42. The particle composition of claim 1, wherein the biologically active molecule is more than about 0.1 mg/ml soluble in the hydrophobic phase.

43. The particle composition of claim 1, wherein the biologically active molecule is more than about 1 mg/ml soluble in the hydrophobic phase.

44. The particle composition of claim 1, wherein said composition is in the form of a suspension.

45. The particle composition of claim 44, wherein the particle size of said suspension is in the range of about 10 nm to 10,000 about nm.

46. The particle composition of claim 44, wherein the particle size of said suspension is in the range of about 10 nm to about 1,000 nm.

47. A method for preventing, treating or ameliorating one or more symptoms associated with a disease or disorder in an animal comprising administering to an animal a composition according to any of claims 1-23, 25-39, 41-44, or 45.

48. A method for preventing, treating or ameliorating one or more symptoms associated with a disease or disorder in an animal comprising administering to an animal a composition according to claim 24.

49. A method for preventing, treating or ameliorating one or more symptoms associated with a disease or disorder in an animal comprising administering to an animal a composition according to claim 40.

50. A method for diagnosing a disease or disorder in an animal comprising administering to said animal a composition according to any one of claims 1-23, 25-39, 41-44, or 45.

51. A method for diagnosing a disease or disorder in an animal comprising administering to said animal a composition according to claim 24.

52. A method for diagnosing a disease or disorder in an animal comprising administering to said animal a composition according to claim 40.

53. The method according to any one of claims 47-50, or 51 wherein the composition is administered as a capsule, soft elastic gelatin capsule, caplet, aerosol, spray, solution, suspension, emulsion, sachet, tablet, capsule, powder or granules.

54. The method according to any one of claims 47-52, or 53, wherein said mammal is a human.

55. The method according to any one of claims 47-52, or 53, wherein the composition is administered orally.

56. The method according to any one of claims 47-52, or 53, wherein the polymeric stabilizer is a natural polymer, a synthetic polymer or a mixture thereof.

57. The particle composition of claim 41 wherein the topoisomerase inhibitor is selected from the group consisting of etoposide, camptothecin, topotecan or a derivative thereof.

58. A method for orally administering paclitaxel to a patient comprising administering the composition of claim 40 to a patient at a dose of paclitaxel in the range of about 10 mg/m² to about 1,000 mg/m².